Aspira Women's Health Inc. Market Research Report

Background

Company Overview

Aspira Women's Health Inc. is a bio-analytical women's health company specializing in the development and commercialization of non-invasive, AI-powered diagnostic tests for gynecologic diseases, with a primary focus on ovarian cancer and endometriosis. The company's mission is to transform women's health through innovative testing solutions that empower patients and healthcare providers in achieving optimal gynecologic care. Aspira's flagship product, OvaSuite™, comprises OvaWatch® and Ova1Plus®, offering a comprehensive portfolio of blood tests to assess the risk of ovarian cancer in women with adnexal masses.

Mission and Vision

Aspira Women's Health is dedicated to advancing women's health by providing cutting-edge diagnostic tools that enable early detection and personalized treatment strategies for gynecologic conditions. The company's vision is to be a leader in women's health diagnostics, improving patient outcomes through innovative, non-invasive testing solutions.

Industry Significance

In the competitive diagnostics market, Aspira Women's Health distinguishes itself by focusing on non-invasive, AI-driven diagnostics for gynecologic diseases. This specialization addresses critical unmet needs in women's health, particularly in the early detection and management of ovarian cancer and endometriosis. The company's innovative approach positions it as a significant player in the women's health diagnostics sector.

Key Strategic Focus

Core Objectives

Innovation in Diagnostics: Develop and commercialize advanced, non-invasive diagnostic tests for gynecologic diseases.

Market Expansion: Increase adoption of OvaSuite™ products among healthcare providers and patients.

Operational Efficiency: Enhance operational processes to improve profitability and reduce costs.

Areas of Specialization

Ovarian Cancer Diagnostics: Providing tools to assess the risk of ovarian malignancy in women with adnexal masses.

Endometriosis Diagnostics: Developing tests to identify endometriomas and endometriosis, addressing a significant diagnostic challenge.

Key Technologies Utilized

AI-Powered Algorithms: Leveraging artificial intelligence to analyze complex biomarker data for accurate risk assessment.

Multi-Omic Approaches: Combining protein and microRNA biomarkers with patient data to enhance diagnostic precision.

Primary Markets Targeted

Healthcare Providers: Hospitals, clinics, and laboratories seeking advanced diagnostic tools for gynecologic diseases.

Patients: Women at risk for ovarian cancer or endometriosis, requiring non-invasive diagnostic options.

Financials and Funding

Funding History

Aspira Women's Health has secured funding through various channels, including private placements and warrant exercises. In September 2025, the company raised approximately $3.06 million through a private placement and warrant exercise, with net proceeds intended to support ongoing commercial activities and general corporate purposes.

Recent Funding Rounds

September 2025: Raised $3.06 million through a private placement and warrant exercise.

July 2024: Completed a warrant exercise transaction with gross proceeds of $2.1 million.

Notable Investors

The private placement in September 2025 included participation from existing and new accredited investors, including members of the Board of Directors.

Utilization of Capital

The funds raised are allocated to support Aspira's ongoing commercial activities, general corporate purposes, and working capital needs.

Pipeline Development

Key Pipeline Candidates

ENDOinform: A non-invasive blood-based diagnostic test utilizing protein and microRNA biomarkers, combined with patient data and AI algorithms, to aid in diagnosing endometriosis in symptomatic patients.

Stages of Development

ENDOinform: The development program received a $10 million award from the Advanced Research Projects Agency for Health (ARPA-H) in October 2024. However, in June 2025, ARPA-H terminated the contract, stating that Aspira had not met the specifications of Milestone 3 in the development program.

Target Conditions

ENDOinform: Endometriosis, a chronic condition affecting millions of women worldwide.

Anticipated Milestones

ENDOinform: Despite the termination of the ARPA-H contract, Aspira aims to complete the ENDOinform program by 2026.

Technological Platform and Innovation

Proprietary Technologies

OvaSuite™: A comprehensive portfolio of non-invasive blood tests, including OvaWatch® and Ova1Plus®, designed to assess the risk of ovarian cancer in women with adnexal masses.

Significant Scientific Methods

AI-Powered Algorithms: Utilizing artificial intelligence to analyze complex biomarker data for accurate risk assessment.

Multi-Omic Approaches: Combining protein and microRNA biomarkers with patient data to enhance diagnostic precision.

Leadership Team

Executive Leadership

Mike Buhle: Chief Executive Officer (CEO) since January 2025, with over 25 years of experience in the clinical and life sciences sectors, specializing in business development, marketing, operations, and strategic partnerships.

Brian Hungerford, CPA, CGMA: Chief Financial Officer (CFO) since September 2025, bringing more than 20 years of executive finance experience across public and private companies, with expertise in SEC reporting, process improvement, and systems implementation.

Dr. Todd Pappas, Ph.D.: Chief Science Officer (CSO), with 25 years of experience in research and product development across oncology and infectious disease, holding key leadership roles in clinical research, regulatory affairs, and diagnostic innovation.

Competitor Profile

Market Insights and Dynamics

The women's health diagnostics market is competitive, with several companies offering diagnostic assays for ovarian cancer and endometriosis. Aspira Women's Health competes with companies such as Fujirebio Diagnostics, which offers the ROMA test, and other entities like Becton Dickinson, ArrayIt Corporation, and Abbott Laboratories, which have publicly disclosed work on ovarian cancer diagnostic assays.

Competitor Analysis

Fujirebio Diagnostics: Offers the ROMA test, combining two tumor markers and menopausal status into a numerical score using a publicly available algorithm.

Becton Dickinson, ArrayIt Corporation, and Abbott Laboratories: Have publicly disclosed work on ovarian cancer diagnostic assays, representing potential competition in the market.

Strategic Collaborations and Partnerships

Co-Marketing and Distribution

In November 2024, Aspira Women's Health expanded its co-marketing and distribution collaboration with BioReference Health, LLC, a subsidiary of OPKO Health Inc., to include OvaWatch®. This partnership aims to provide the entire OvaSuite™ portfolio to healthcare providers in New York and New Jersey, enhancing market reach and adoption of Aspira's diagnostic tests.

Operational Insights

Strategic Considerations

Aspira Women's Health operates in a competitive diagnostics market, facing challenges from established companies with extensive resources. The company's focus on non-invasive, AI-powered diagnostics for gynecologic diseases differentiates it from competitors and addresses critical unmet needs in women's health. Strategic collaborations, such as the expanded partnership with BioReference Health, are essential for enhancing market presence and driving growth.